Discover IRBM’s expertise through a wide range of content covering various therapeutic areas and the latest drug discovery techniques. Gain insights into how we tackle challenges, drive discovery programs, and support your research with services ranging from target validation and hit finding to candidate nomination.

IRBM is a leading research organization with extensive experience in transforming early-stage science into advanced drug discovery programs. Specializing in cancer, neurological disorders, infection, and rare diseases, we offer both comprehensive and specialized services throughout the drug discovery process.

IRBM Science Park è un gruppo aziendale italiano che opera nel settore della biotecnologia molecolare, della scienza biomedicale e della chimica organica.

IRBM is a drug discovery CRO with expertise ranging from target validation and hit finding to preclinical candidate nomination across various therapeutic areas, including oncology, infectious diseases, and neuroscience.

IRBM is a research organization working across all aspects of preclinical drug discovery and early development. IRBM fosters collaborations with the pharmaceutical, biotech and academic sectors...

Find company research, competitor information, contact details & financial data for IRBM SPA of POMEZIA, ROMA. Get the latest business insights from Dun & Bradstreet.

IRBM has developed unique expertise in advancing integrated drug discovery projects, having delivered 25 preclinical candidates and four drugs that are currently on the market. With all their world-class facilities on-site, fully integrated programs are executed under one roof. IRBM works with pharmaceutical companies, non-profit organizations and

AM E3: 一种TSLPR抑制剂药物，由IRBM SpA (IRBM SpA)公司最早进行研发，目前全球最高研发状态为临床前，作用机制: TSLPR抑制剂(cytokine receptor like factor 2 inhibitors)，治疗领域: 肿瘤,免疫系统疾病,血液及淋巴系统疾病，在研适应症: 急性淋巴细胞白血病，在研机构: IRBM SpA。

了解IRBM Science Park SpA (IRBM Science Park SpA)公司的药物管线，治疗领域，技术平台，以及它的22篇文献，疾病领域:神经系统疾病，肿瘤，技术平台:化学药，药物:I-1000233，MW-559。

2024年10月11日 · IRBM is an innovative contract research organization working across all aspects of drug discovery and early development for different modalities – small molecule, peptides and antibodies. We foster collaborations with organizations from the pharmaceutical, biotech and academic sectors to accelerate drug discovery from target validation and ...